Piper Sandler initiated coverage of Viking Therapeutics (VKTX) with an Overweight rating and $74 price target The company has generated one of the more compelling weight loss profiles in Phase 2 with VK2735 in conjunction with lower discontinuation rates in obese patients, the analyst tells investors in a research note. Piper also thinks Viking has a potentially “best” oral incretin with oral VK2735 which has observed lower rates of adverse events and competitive efficacy relative to other incretins currently in development.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VKTX:
- Viking’s VK2735 outpacing Amgen’s MariTide, says H.C. Wainwright
- Positive Phase 2 Trial Results Drive Viking Therapeutics (VKTX) Stock Upwards
- Viking Therapeutics initiated with a Buy at B. Riley
- Viking Therapeutics reports results from Phase 2b clinical trial of VK2809
- Viking to present data from Phase 2b VOYAGE study in late breaker presentation